Aclarion Publishes 2026 Shareholder Letter from the Chairman
Rhea-AI Summary
Aclarion (Nasdaq: ACON) published its 2026 shareholder letter outlining clinical, financial, and operational priorities. The company expects an initial internal readout of its 300-patient CLARITY trial at the end of Q3 2026 and plans a public disclosure of early interim results in Q4 2026.
Key facts: cash runway into 2028, ATM terminated in early 2025, ELOC expired December 31, 2025, and 2,882,371 fully diluted shares outstanding. The company emphasizes a cloud-delivered, software-native MedTech model and will pursue an investor-awareness program focused on institutional healthcare investors and physician education.
Positive
- Cash runway into 2028 provides funding through the CLARITY initial readout
- Software-native, cloud-delivered model enables software-level gross margins and scalability
- 300-patient CLARITY trial on track with internal readout expected end of Q3 2026
Negative
- No remaining ATM or ELOC
- Public disclosure of only early interim results in Q4 2026 leaves commercial milestones dependent on trial data
Key Figures
Market Reality Check
Peers on Argus
Two sector peers in the momentum scan moved down (median move about -14.8%), while broader peers showed mixed single‑stock moves, indicating broader sector weakness but unclear direct alignment with ACON.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 03 | Commercial partnership | Positive | -2.1% | Expanded Nociscan use via Source Healthcare to build real‑world evidence. |
| Jan 13 | Financing / runway | Positive | -6.9% | Closed $10.4M equity financing, lifting cash to $21.6M and runway into 2028. |
| Jan 08 | Outlook & metrics | Positive | +42.1% | Reported strong 2025 scan growth, higher cash, and extended runway into H1 2027. |
| Jan 06 | Trial enrollment | Positive | +3.7% | Additional CLARITY sites enrolling; outlined 300-patient design and interim timeline. |
| Dec 04 | Clinical publication | Positive | +5.0% | IJSS article showcased Nociscan-guided surgical decision leading to pain relief. |
Recent news has often been clinically and financially positive, yet share reactions have been mixed, with balance sheet and financing updates sometimes met with weakness.
Over the past few months, Aclarion has focused on Nociscan adoption, CLARITY trial progress, and balance sheet strengthening. A Dec 4, 2025 journal article and multiple CLARITY updates highlighted clinical validation efforts. In October 2025 and January 2026, the company raised capital through registered direct offerings, extending runway and remaining debt-free. A Jan 8, 2026 outlook and a Feb 3, 2026 partnership emphasized growth and real‑world evidence. Today’s shareholder letter reiterates these themes around runway into 2028 and trial milestones.
Market Pulse Summary
This announcement emphasizes Aclarion’s extended cash runway into 2028, the absence of an active ATM or ELOC, and a fully diluted share count of 2,882,371, signaling a focus on limiting dilution ahead of CLARITY readouts. It reiterates the pivotal 300-patient trial with internal data expected by end of Q3 2026 and interim disclosure in Q4 2026. Investors may watch clinical timelines, execution of the investor-awareness strategy, and any future financing decisions once interim data are available.
Key Terms
biomarkers medical
mr spectroscopy medical
AI-generated analysis. Not financial advice.
- Company anticipates no capital raises prior to expected value enhancing catalysts
- Cash runway into 2028
- ATM terminated in early 2025 and ELOC expired December 31, 2025
BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of its 2026 Shareholder Letter from the Chairman. The letter outlines significant clinical, financial, and operational priorities as the company advances toward an expected initial internal readout of its 300-patient CLARITY trial at the end of Q3 and an expected public disclosure of early interim results in Q4 of 2026.
“Aclarion enters 2026 with a strengthened balance sheet, a scalable software-native business model, and a clear path to an initial readout on our CLARITY trial,” said Jeff Thramann, Executive Chairman of Aclarion. “With cash runway into 2028 and a clean capital structure, we are fully funded to deliver this important clinical milestone. Our focus is on ensuring that the value created by our early data accrues directly to our existing shareholders as we continue advancing a technology that provides physicians with objective biochemical insights to support better decision-making for patients suffering from chronic low back pain.”
The company highlighted its strengthened financial position. Following recent financings, the company reiterated it now has a cash runway into 2028, providing the resources needed to complete the CLARITY trial and operate through the initial data readout without raising additional capital. To reinforce this commitment to shareholder alignment, Aclarion no longer has an ATM in place and its ELOC expired at the end of 2025. The Company currently has 2,882,371 shares outstanding on a fully diluted basis and will not be putting a new ATM or ELOC in place until after it reports on the initial interim CLARITY results.
Aclarion also emphasized its position as part of a new generation of software-native MedTech innovators that, unlike traditional device companies, deliver its solution entirely through the cloud. This enables software-level gross margins, rapid scalability, and continuous algorithmic improvement without manufacturing or inventory constraints.
In 2026, the company will be executing a structured investor-awareness strategy focused on institutional healthcare investors, physician-led clinical education, and increased visibility in financial and medical media.
The full 2026 Shareholder Letter is available on the company’s website at: https://investors.aclarion.com/news
For more News from Aclarion, please visit: Latest News
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trials, the expected initial internal readout of its 300-patient CLARITY trial at the end of Q3 2026 and an expected public disclosure of early interim results in Q4 of 2026, having a cash runway into 2028, providing the resources needed to complete the CLARITY trial and operate through the initial data readout without raising additional capital, the Company will not be putting a new ATM or ELOC in place until after it reports on the initial interim CLARITY results, the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jessica Starman
media@elev8newmedia.com
FAQ
When will Aclarion (ACON) report the initial CLARITY trial readout in 2026?
Does Aclarion (ACON) have enough cash to reach its CLARITY milestone?
What capital markets tools does Aclarion (ACON) currently have in place?
How many fully diluted shares does Aclarion (ACON) report?
What is Aclarion's (ACON) business model and operational advantage?
